FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1469-1470 May 30, 1996 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Acute respiratory distress syndrome (ARDS) continues to be a major cause of morbidity and mortality in critically ill patients. In this issue of the Journal, Anzueto et al.¹ report the results of a large, multicenter, randomized trial that was carried out to evaluate the potential benefit of aerosolized surfactant therapy in patients with ARDS. Disappointingly, there was no benefit. It is important to analyze the results of this trial carefully, so that the possibility of success in future trials can be maximized.

Although the cellular and molecular mechanisms that cause injury to the lung may not be the same in . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.